We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI Predicts Tumor-Killing Cells with High Accuracy

By LabMedica International staff writers
Posted on 16 May 2024
Print article
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body. T cells, a primary type of white blood cell or lymphocyte, circulate in the blood and monitor for virally infected or cancerous cells. Among these, T cells that infiltrate solid tumors are known as tumor-infiltrating lymphocytes, or TILs. However, not all TILs effectively recognize and attack tumor cells. To address this, scientists have now employed artificial intelligence (AI) to create a predictive model that can identify the most effective TILs for use in cancer immunotherapy.

The new AI-driven predictive model, called TRTpred developed by scientists at Ludwig Cancer Research (New York, NY, USA) ranks T cell receptors (TCRs) according to their tumor reactivity. To create TRTpred, the researchers utilized 235 TCRs from patients with metastatic melanoma, already categorized as tumor-reactive or non-reactive. They input the global gene-expression profiles of the T cells harboring each TCR into a machine learning model to identify patterns distinguishing tumor-reactive T cells from their inactive counterparts. This model, enhanced with additional algorithms, supports personalized cancer treatments tailored to the unique cellular composition of each patient’s tumors.

The TRTpred model was used to analyze TILs from 42 patients with melanoma, gastrointestinal, lung, and breast cancer, pinpointing tumor-reactive TCRs with about 90% accuracy. The selection process was further refined using a secondary algorithmic filter to isolate those T cells with “high avidity”—meaning they bind strongly to tumor antigens. It was observed that T cells identified by TRTpred and this secondary filter as both tumor-reactive and high avidity were predominantly located within the tumors rather than in the surrounding stromal tissue. This aligns with previous studies suggesting that effective T cells often deeply penetrate tumor islets.

A third filter was then introduced to enhance the identification of TCRs recognizing a diverse array of tumor antigens. This filter groups TCRs based on similar physical and chemical characteristics, assuming TCRs in each group recognize the same antigen. This enhanced system, named MixTRTpred, was then tested by growing human tumors in mice, extracting TCRs from their TILs, and employing MixTRTpred to identify T cells that were tumor-reactive, had high avidity, and targeted multiple tumor antigens. The researchers then engineered mouse T cells to express these TCRs and demonstrated that these modified cells could effectively eradicate tumors when reintroduced into the mice.

“The implementation of artificial intelligence in cellular therapy is new and may be a game-changer, offering new clinical options to patients,” said Ludwig Lausanne’s Alexandre Harari, who led the study published on May 7, 2024 in Nature Biotechnology.

Related Links:
Ludwig Cancer Research

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Uric Acid and Blood Glucose Meter
URIT-10
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.